Incyte to Present Multiple Studies from Dermatology Portfoli

Incyte (NASDAQ:INCY) today announced multiple abstracts featuring new data from across its dermatology portfolio have been accepted for presentation at the upcoming European Academy of Dermatology and Venereology (EADV)

Related Keywords

Quebec , Canada , United States , Germany , Delaware , Berlin , Hidradenitis Suppurativa , Jim Lee , Exchange Commission , European Academy Of Dermatology , Group Vice , Free Communications , Us Food Drug Administration , European Academy , Group Vice President , Extensive Vitiligo , Week Results , Dose Ranging Phase , Late Breaking , Prolonged Ruxolitinib Cream Treatment , Vitiligo Among Patients , Ruxolitinib Cream , Children Aged , Disease Characteristics Associated , Secondary Analysis , Placebo Controlled Clinical Trial , Placebo Controlled Phase , Body Region Through Week , Ev Long Term Extension Phase , Ruxolitinib Cream Through Week , Subgroup Analysis , Occurred Among Individuals , Applied Ruxolitinib Cream , Two Randomized Phase , Depressive Symptoms Among Persons Living , Cessation Among Patients Living , Database Analysis , Treatment Patterns , Maximum Use Trial , Sustained Reduction , Atopic Dermatitis Applying Ruxolitinib Cream , Translational Results , Open Label Phase , Drug Administration ,